OmniAb (OABI) Stock Forecast: StockMap's 2-Week Call

OABI stock forecast: StockMap's model makes no two-week call on OmniAb after the Nov 13 close: its evidence is split, 5 reasons for and 10 against. Too few two-week windows graded to judge yet.

OmniAb last closed at $4.91, -0.81% on the session.

Against the IVW growth benchmark the position is +0.10% over the forecast window.

OmniAb's market cap is $716.16M as of November 13, 2026.

No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 15 (too close to call).

Where OABI sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 33%.

10 daily calls for OABI so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks OmniAb in the 28th percentile on return on equity, where 100 is best.

OmniAb is classified under Health Care / Life Sciences Tools & Services.

StockMap tracks OmniAb as the 33rd largest of the 42 companies it covers in the Life Sciences Tools & Services industry, part of the Health Care sector.

Across that group the current two-week reads are 25 Neutral, 13 Moderate Outperform, 3 Moderate Underperform and 1 Strong Underperform.

On that composite OmniAb ranks 18th of 42 in the group, against a group median of +0.13.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 13, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

OmniAb (OABI) — StockMap 2-week forecast & tracked accuracy